Spyre Therapeutics, Inc.
SYREHealthcareNASDAQBiotechnology · Last scanned Sep 5, 2026
Scan Results
Daily timeframeSpyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The $7.85B market capitalization puts SYRE squarely in mid-cap range for its industry. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Market Cap
$7.85B
Beta
3.00
P/E (TTM)
—
P/E (Fwd)
-25.91
EPS (TTM)
$-1.96
EPS (Fwd)
$-3.43
ROE
-23.0%
ROA
-19.8%
Cash
$1.15B
Total Debt
$0
Free CF
-$89.1M
52W Change
413.2%
Annual Financials
Cash vs Debt
Where SYRE stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SYRE finished 21.97% above its 150-day moving average ($71.37) and 41.91% above its 200-day moving average ($61.34). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SYRE overbought or oversold?
At the September 3, 2026 close, SYRE's RSI(14) was 25.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Spyre Therapeutics, Inc. reports $1.15B in cash and $0 in total debt. Free cash flow is running at -$89.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -23.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $2.3M (2022) to $0 (2025), a 100% decline worth watching.
Spyre Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Spyre Therapeutics, Inc. and its sector.